This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fang, J. Articles by Moses, M. A. Search for Related Content PubMed PubMed Citation Articles by Fang, J. Articles by Moses, M. A.

HIF-1-mediated Up-Regulation of Vascular Endothelial Growth Factor, Independent of Basic Fibroblast Growth Factor, Is Important in the Switch to the Angiogenic Phenotype during Early Tumorigenesis¹

Laboratory for Surgical Research, Department of Surgery, Children’s Hospital, and Department of Surgery, Harvard Medical School, Boston, Massachusetts 02115

The switch to the angiogenic phenotype represents a critical checkpoint during tumor progression. The acquisition of new capillary vessels provides newly vascularized tumor nodules with a distinct biological advantage over their avascular counterparts by conferring upon them the ability to expand and develop both locally and metastatically. To identify the molecules and mechanisms underlying this rate-limiting step in successful tumorigenesis, we have developed an in vivo tumor model that reproducibly recapitulates the angiogenic switch. Using this model, we have analyzed vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and hypoxia-inducible factor-1 (HIF-1) expression and activity in both avascular and vascular growth phases of the tumor. A significantly higher level of VEGF protein was detected in avascular tumor nodules compared with vascular nodules. As avascular tumors became vascularized, VEGF levels decreased 10-fold. In contrast, bFGF levels were not elevated in avascular nodules but rather were detected at levels 2 times higher in vascular nodules compared with the avascular tumor nodules. Given that VEGF is transcriptionally regulated by HIF-1, immunohistochemical studies of chondrosarcoma nodules were conducted and revealed that the nuclear translocation of HIF-1 was detected exclusively in avascular tumor nodules. This study implicates HIF-1-mediated up-regulation of VEGF but not bFGF in the switch to the angiogenic phenotype during tumorigenesis.

This article has been cited by other articles:

				K. A. Brant and J. P. Fabisiak Nickel and the Microbial Toxin, MALP-2, Stimulate Proangiogenic Mediators from Human Lung Fibroblasts via a HIF-1{alpha} and COX-2-Mediated Pathway Toxicol. Sci., January 1, 2009; 107(1): 227 - 237. [Abstract] [Full Text] [PDF]

				Q. Li, S. Yano, H. Ogino, W. Wang, H. Uehara, Y. Nishioka, and S. Sone The Therapeutic Efficacy of Anti Vascular Endothelial Growth Factor Antibody, Bevacizumab, and Pemetrexed against Orthotopically Implanted Human Pleural Mesothelioma Cells in Severe Combined Immunodeficient Mice Clin. Cancer Res., October 1, 2007; 13(19): 5918 - 5925. [Abstract] [Full Text] [PDF]

				J. Harper, L. Yan, R. M. Loureiro, I. Wu, J. Fang, P. A. D'Amore, and M. A. Moses Repression of Vascular Endothelial Growth Factor Expression by the Zinc Finger Transcription Factor ZNF24 Cancer Res., September 15, 2007; 67(18): 8736 - 8741. [Abstract] [Full Text] [PDF]

				E. Daghini, X.-Y. Zhu, D. Versari, M. D. Bentley, C. Napoli, A. Lerman, and L. O. Lerman Antioxidant vitamins induce angiogenesis in the normal pig kidney Am J Physiol Renal Physiol, July 1, 2007; 293(1): F371 - F381. [Abstract] [Full Text] [PDF]

				J. R. Basile, K. Holmbeck, T. H. Bugge, and J. S. Gutkind MT1-MMP Controls Tumor-induced Angiogenesis through the Release of Semaphorin 4D J. Biol. Chem., March 2, 2007; 282(9): 6899 - 6905. [Abstract] [Full Text] [PDF]

				S. Yano, H. Muguruma, Y. Matsumori, H. Goto, E. Nakataki, N. Edakuni, H. Tomimoto, S. Kakiuchi, A. Yamamoto, H. Uehara, et al. Antitumor Vascular Strategy for Controlling Experimental Metastatic Spread of Human Small-Cell Lung Cancer Cells with ZD6474 in Natural Killer Cell-Depleted Severe Combined Immunodeficient Mice Clin. Cancer Res., December 15, 2005; 11(24): 8789 - 8798. [Abstract] [Full Text] [PDF]

				D. J. Davidson, C. Haskell, S. Majest, A. Kherzai, D. A. Egan, K. A. Walter, A. Schneider, E. F. Gubbins, L. Solomon, Z. Chen, et al. Kringle 5 of Human Plasminogen Induces Apoptosis of Endothelial and Tumor Cells through Surface-Expressed Glucose-Regulated Protein 78 Cancer Res., June 1, 2005; 65(11): 4663 - 4672. [Abstract] [Full Text] [PDF]

				K. Brusselmans, F. Bono, D. Collen, J.-M. Herbert, P. Carmeliet, and M. Dewerchin A Novel Role for Vascular Endothelial Growth Factor as an Autocrine Survival Factor for Embryonic Stem Cells during Hypoxia J. Biol. Chem., February 4, 2005; 280(5): 3493 - 3499. [Abstract] [Full Text] [PDF]

				A. B. Heimberger, E. Wang, E. C. McGary, K. R. Hess, V. K. Henry, T. Shono, Z. Cohen, J. Gumin, R. Sawaya, C. A. Conrad, et al. Mechanisms of action of rapamycin in gliomas Neuro-oncol, January 1, 2005; 7(1): 1 - 11. [Abstract] [PDF]

				H. Yoshimura, D. K. Dhar, H. Kohno, H. Kubota, T. Fujii, S. Ueda, S. Kinugasa, M. Tachibana, and N. Nagasue Prognostic Impact of Hypoxia-Inducible Factors 1{alpha} and 2{alpha} in Colorectal Cancer Patients: Correlation with Tumor Angiogenesis and Cyclooxygenase-2 Expression Clin. Cancer Res., December 15, 2004; 10(24): 8554 - 8560. [Abstract] [Full Text] [PDF]

				A. Hoeben, B. Landuyt, M. S. Highley, H. Wildiers, A. T. Van Oosterom, and E. A. De Bruijn Vascular Endothelial Growth Factor and Angiogenesis Pharmacol. Rev., December 1, 2004; 56(4): 549 - 580. [Abstract] [Full Text] [PDF]

				O. Stoeltzing, M. F. McCarty, J. S. Wey, F. Fan, W. Liu, A. Belcheva, C. D. Bucana, G. L. Semenza, and L. M. Ellis Role of Hypoxia-Inducible Factor 1{alpha} in Gastric Cancer Cell Growth, Angiogenesis, and Vessel Maturation J Natl Cancer Inst, June 16, 2004; 96(12): 946 - 956. [Abstract] [Full Text] [PDF]

				T. A. Zaichuk, E. H. Shroff, R. Emmanuel, S. Filleur, T. Nelius, and O. V. Volpert Nuclear Factor of Activated T Cells Balances Angiogenesis Activation and Inhibition J. Exp. Med., June 7, 2004; 199(11): 1513 - 1522. [Abstract] [Full Text] [PDF]

				R. A. Nordal, A. Nagy, M. Pintilie, and C. S. Wong Hypoxia and Hypoxia-Inducible Factor-1 Target Genes in Central Nervous System Radiation Injury: A Role for Vascular Endothelial Growth Factor Clin. Cancer Res., May 15, 2004; 10(10): 3342 - 3353. [Abstract] [Full Text] [PDF]

				L. Wang, N. Wakisaka, C. C Tomlinson, S. M DeWire, S. Krall, J. S Pagano, and B. Damania The Kaposi's Sarcoma-Associated Herpesvirus (KSHV/HHV-8) K1 Protein Induces Expression of Angiogenic and Invasion Factors Cancer Res., April 15, 2004; 64(8): 2774 - 2781. [Abstract] [Full Text] [PDF]

				G. Hopfl, O. Ogunshola, and M. Gassmann HIFs and tumors--causes and consequences Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2004; 286(4): R608 - R623. [Abstract] [Full Text] [PDF]

				S. Welsh, R. Williams, L. Kirkpatrick, G. Paine-Murrieta, and G. Powis Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1{alpha} Mol. Cancer Ther., March 1, 2004; 3(3): 233 - 244. [Abstract] [Full Text]

				K. S. Moulton, K. Vakili, D. Zurakowski, M. Soliman, C. Butterfield, E. Sylvin, K.-M. Lo, S. Gillies, K. Javaherian, and J. Folkman Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis PNAS, April 15, 2003; 100(8): 4736 - 4741. [Abstract] [Full Text] [PDF]

				X. H. Liu, A. Kirschenbaum, M. Lu, S. Yao, A. Dosoretz, J. F. Holland, and A. C. Levine Prostaglandin E2 Induces Hypoxia-inducible Factor-1alpha Stabilization and Nuclear Localization in a Human Prostate Cancer Cell Line J. Biol. Chem., December 13, 2002; 277(51): 50081 - 50086. [Abstract] [Full Text] [PDF]

				C. N. Coleman, J. B. Mitchell, and K. Camphausen Tumor Hypoxia: Chicken, Egg, or a Piece of the Farm? J. Clin. Oncol., February 1, 2002; 20(3): 610 - 615. [Full Text] [PDF]